Rankings
▼
Calendar
TEVA Q3 2020 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena
TEVA
Teva Pharmaceutical Industries Limited
$36B
Q3 2020 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$4.0B
-6.7% YoY
Gross Profit
$1.9B
46.6% margin
Operating Income
-$4.3B
-109.2% margin
Net Income
-$4.3B
-109.3% margin
EPS (Diluted)
$-3.97
QoQ Revenue Growth
+2.8%
Cash Flow
Operating Cash Flow
$307M
Free Cash Flow
$164M
Stock-Based Comp.
$29M
Balance Sheet
Total Assets
$49.7B
Total Liabilities
$39.1B
Stockholders' Equity
$9.6B
Cash & Equivalents
$1.8B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4.0B
$4.3B
-6.7%
Gross Profit
$1.9B
$1.8B
+1.3%
Operating Income
-$4.3B
-$81M
-5260.5%
Net Income
-$4.3B
-$314M
-1285.0%
Revenue Segments
Product
$3.4B
86%
Distribution Service
$350M
9%
Product and Service, Other
$174M
4%
License
$27M
1%
Geographic Segments
North America Segment
$2.0B
55%
Europe Segment
$1.1B
30%
International Markets
$529M
14%
← FY 2020
All Quarters
Q4 2020 →